CMXCD 

$0.34
0
+$0+0% Wednesday 13:30

Statistics

Day High
0.43
Day Low
0.43
52W High
0.48
52W Low
0.22
Volume
372
Avg. Volume
1,003
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-566,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CMXCD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap22.71B
Dexcom, Inc. specializes in glucose monitoring systems, competing in the medical device sector focused on diabetes management, similar to Cell MedX's focus.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care, Inc. provides innovative insulin delivery systems, directly competing in the diabetes care market where Cell MedX operates.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation manufactures insulin pump technology, aligning with diabetes management solutions, a field relevant to Cell MedX's interests.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers a broad range of medical devices including glucose monitoring systems, competing in the same healthcare segment as Cell MedX.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc provides medical technologies, services, and solutions including diabetes management products, directly competing with Cell MedX's offerings.
Senseonics
SENS
Mkt Cap287.64M
Senseonics Holdings, Inc. focuses on the development of glucose monitoring systems, which is a direct competition to Cell MedX's diabetes-related technologies.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk A/S, a global healthcare company, focuses on diabetes care products, competing in the same therapeutic area as Cell MedX.
Sanofi
SNY
Mkt Cap124.45B
Sanofi S.A. engages in the development and marketing of therapeutic solutions including diabetes care, which competes with Cell MedX's market.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. provides healthcare solutions including diabetes management drugs and therapies, competing in the broader diabetes care market relevant to Cell MedX.

About

Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
Show more...
CEO
Mr. David M. Jeffs
Country
US

Listings

0 Comments

Share your thoughts

FAQ

What is CMXCD stock price today?
The current price of CMXCD is $0.34 USD — it has increased by +0% in the past 24 hours. Watch CMXCD stock price performance more closely on the chart.
What is CMXCD stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange CMXCD stocks are traded under the ticker CMXCD.
Is CMXCD stock price growing?
CMXCD stock has risen by +0% compared to the previous week, the month change is a -22.09% fall, over the last year CMXCD has showed a +30.35% increase.
What is CMXCD revenue for the last year?
CMXCD revenue for the last year amounts to 0 USD.
What is CMXCD net income for the last year?
CMXCD net income for the last year is -566,000 USD.
In which sector is CMXCD located?
CMXCD operates in the Health Care sector.
When did CMXCD complete a stock split?
The last stock split for CMXCD was on November 05, 2024 with a ratio of 1:15.
Where is CMXCD headquartered?
CMXCD is headquartered in Carson City, US.